A carregar...
Shift From Adalimumab Originator to Biosimilars in Denmark
This study describes the nationwide shift from brand-name adalimumab (originator) to adalimumab biosimilars in Denmark and analyzes what a similar shift in the US would look like.
Na minha lista:
| Publicado no: | JAMA Intern Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7105946/ https://ncbi.nlm.nih.gov/pubmed/32227137 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2020.0338 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|